aibio
Company Updates ·
Damora completes move from Delaware to the Cayman Islands
Damora Therapeutics completed its redomestication effective July 16, 2026. Its ordinary shares trade on Nasdaq under a new CUSIP from July 20, 2026.
DMRA Damora Therapeutics, Inc.
Damora Therapeutics (DMRA) news DMRA offering news
Latest Damora Therapeutics news
- Financings
Galecto (now Damora Therapeutics) issues warrant for up to 628,302 shares, names new COO
The December 31, 2025 warrant went to Paramora Holding LLC at $23.01 per share under an October 7, 2025 option agreement with Paragon Therapeutics. The board named Sherwin Sattarzadeh Chief Operating Officer.
- Mergers
Galecto (now Damora Therapeutics) buys Damora, agrees to about $285 million private placement
Galecto completed its acquisition of Damora Therapeutics on November 10, 2025. A concurrent private placement of Series C preferred stock for approximately $285 million is expected to close November 12.
Damora Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $26.9 million | $6.4 million |
| Net income (loss) | -$209.8 million | -$21.4 million |
| Cash from operations | -$6.7 million | -$18.6 million |
| Cash and equivalents | $257.6 million | $14.2 million |
Questions about Damora Therapeutics
Has Damora Therapeutics raised money recently?
Our latest story on this, dated Nov 10, 2025: "Galecto (now Damora Therapeutics) buys Damora, agrees to about $285 million private placement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Damora Therapeutics?
Damora Therapeutics, Inc. trades under the ticker DMRA on NASDAQ.
Where is Damora Therapeutics listed?
Damora Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Damora Therapeutics?
The SEC Central Index Key (CIK) for Damora Therapeutics, Inc. is 1800315. Its filings are on SEC EDGAR.
How many shares does Damora Therapeutics have outstanding?
61,735,519 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is Damora Therapeutics listed under?
Our directory records Damora Therapeutics, Inc. under United States.
What does Damora Therapeutics do?
Our directory classifies Damora Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Damora Therapeutics?
The ISIN recorded for Damora Therapeutics, Inc. is KYG2646Y1044.
Does aibio.space cover Damora Therapeutics?
aibio.space lists Damora Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Damora Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Damora Therapeutics profitable?
Damora Therapeutics, Inc. reported a net loss of $209.8 million for the fiscal year ended Dec 31, 2025, and used $6.7 million of cash in operations, per its annual report to the SEC.
How much does Damora Therapeutics spend on research and development?
$26.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Damora Therapeutics have?
$540.5 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Damora Therapeutics (DMRA) stock news?
Our latest story on Damora Therapeutics, dated Jul 17, 2026: "Damora completes move from Delaware to the Cayman Islands". Damora Therapeutics completed its redomestication effective July 16, 2026. Its ordinary shares trade on Nasdaq under a new CUSIP from July 20, 2026. Source.
How long will Damora Therapeutics's cash last?
From our story of Jan 6, 2026: Its independent registered public accounting firm included an explanatory paragraph saying the company's losses from operations and need for additional funding raise substantial doubt about its ability to continue as a going concern. Source.
Investor discussion: Damora Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,5.03,8.01,9.01). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Damora Therapeutics, Inc.
- CIK
- 1800315
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- DMRA (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 221 CRESCENT STREET, WALTHAM, MA, 02453
- Phone
- (781) 281-9020
- Shares outstanding
- 61,735,519 as of 2026-08-07 (10-Q filed 2026-08-10)
- Former names
- Galecto, Inc.; Galecto Inc.
Recent filings
Listing details
- Company
- Damora Therapeutics, Inc.
- Ticker
- DMRA
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- KYG2646Y1044
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction